Health Care

Ardelyx insider buy: Chief Patient Officer Laura Williams snaps up 50,000 shares at $0.99 amid rising social buzz, signaling confidence in IBSRELA & XPHOZAH pipeline.

Apellis insider Watson David O. buys 888 shares at $14.95, betting on the company’s bullish rally and upcoming data from the J.P. Morgan Healthcare Conference.

Merger‑driven insider moves at Cidara reveal how RA Capital streamlined its holdings for Merck, turning shares into cash and ending public trading.

Joshua Levine’s 25,000‑share holding in EDAP TMS SA signals board confidence, suggesting the stock is still undervalued amid its recent rally.

Insider selling spurs caution at Acumen Pharmaceuticals: high-volume, low-price sales hint at confidence doubts amid a volatile biotech cycle.

Enliven Therapeutics’ insider buying spurs optimism after promising Phase 1b results, but investors should stay cautious amid high volatility.

IQVIA insider buys reveal strong leadership confidence and a bullish outlook—discover why executives are buying, the SAR strategy, and what it means for investors.

Discover why aTyr Pharma’s CFO buying 412,500 zero‑cost stock options signals long‑term confidence, the risks for investors, and what it means for the company’s future.

Celcuity insider sale: What Nigon Richard’s 19,975‑share move reveals about the stock’s future momentum and risk.

Insider buying spree at Sellas signals confidence in its oncology pipeline, hinting at upcoming clinical breakthroughs and potential stock rally.